OLMA logo

Olema Pharmaceuticals (OLMA) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

19 November 2020

Indexes:

Not included

Description:

Olema Pharmaceuticals, or OLMA, is a biopharmaceutical company focused on developing innovative treatments for cancer. They work on targeted therapies to improve patient outcomes and aim to address unmet medical needs in oncology. Their research emphasizes precision medicine to provide effective solutions for various cancer types.

Events Calendar

Earnings

Next earnings date:

Mar 11, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Mar 11, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

12 Dec '24 HC Wainwright & Co.
Buy
11 Dec '24 HC Wainwright & Co.
Buy
13 Nov '24 HC Wainwright & Co.
Buy
24 Oct '24 HC Wainwright & Co.
Buy
08 Aug '24 JP Morgan
Overweight
07 Aug '24 Oppenheimer
Outperform
07 Aug '24 HC Wainwright & Co.
Buy
04 June '24 HC Wainwright & Co.
Buy
15 May '24 HC Wainwright & Co.
Buy
09 May '24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium
Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium
Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium
OLMA
globenewswire.com25 November 2024

Olema will host an investor conference call at 8:00 a.m. ET on December 10, 2024 Olema will host an investor conference call at 8:00 a.m. ET on December 10, 2024

Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology to Participate in Upcoming Investor Conferences
OLMA
globenewswire.com06 November 2024

SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that its management team will participate in the following upcoming investor conferences:

Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024
Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024
Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024
OLMA
globenewswire.com23 October 2024

SAN FRANCISCO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced results from three preclinical studies that will be presented during poster sessions at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) in Barcelona, Spain.

Olema Oncology to Participate in Upcoming Investor Conferences in June
Olema Oncology to Participate in Upcoming Investor Conferences in June
Olema Oncology to Participate in Upcoming Investor Conferences in June
OLMA
globenewswire.com28 May 2024

SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that its management team will participate in the following upcoming investor conferences:

Olema Oncology to Participate in Upcoming Investor Conferences in May
Olema Oncology to Participate in Upcoming Investor Conferences in May
Olema Oncology to Participate in Upcoming Investor Conferences in May
OLMA
GlobeNewsWire01 May 2024

Olema Pharmaceuticals, Inc. ("Olema", "Olema Oncology", Nasdaq: OLMA), a company developing targeted therapies for women's cancers, shared that its management team will be present at upcoming investor conferences.

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
OLMA
GlobeNewsWire08 April 2024

SAN FRANCISCO, April 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a panel on “Breast Cancer – Shifting an Entrenched Paradigm” at the 2024 CG Horizons in Oncology Virtual Conference on Monday, April 15, 2024, at 2:00 p.m. ET.

Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology to Participate in Upcoming Investor Conferences
OLMA
GlobeNewsWire06 February 2024

SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that the Company will participate in the following upcoming investor conferences:

Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)
Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)
Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)
OLMA
GlobeNewsWire28 November 2023

Presentations detailing initial Phase 1b clinical data for palazestrant in combination with ribociclib, a Poster Spotlight Session on Phase 2 clinical data for palazestrant in combination with palbociclib, and the OPERA-01 Phase 3 clinical trial in progress will be presented on Dec. 7, 2023

Olema Pharmaceuticals: Advancing On Multiple Fronts
Olema Pharmaceuticals: Advancing On Multiple Fronts
Olema Pharmaceuticals: Advancing On Multiple Fronts
OLMA
Seeking Alpha28 November 2023

Today, we revisit Olema Pharmaceuticals, Inc. for the first time in two years. Olema is a clinical-stage biotech company focused on developing therapies for women's cancers. Their primary product candidate, palazestrant, has been granted FDA Fast Track designation for the treatment of metastatic breast cancer. Palazestrant is advancing in development both as a potential monotherapy and as part of potential combination therapies.

Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's Why
Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's Why
Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's Why
OLMA
Zacks Investment Research27 November 2023

Olema's (OLMA) shares surge on the successful development of its lead candidate in metastatic breast cancer indication.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the primary business of Olema Pharmaceuticals?
  • What is the ticker symbol for Olema Pharmaceuticals?
  • Does Olema Pharmaceuticals pay dividends?
  • What sector is Olema Pharmaceuticals in?
  • What industry is Olema Pharmaceuticals in?
  • What country is Olema Pharmaceuticals based in?
  • When did Olema Pharmaceuticals go public?
  • Is Olema Pharmaceuticals in the S&P 500?
  • Is Olema Pharmaceuticals in the NASDAQ 100?
  • Is Olema Pharmaceuticals in the Dow Jones?
  • When was Olema Pharmaceuticals's last earnings report?
  • When does Olema Pharmaceuticals report earnings?
  • Should I buy Olema Pharmaceuticals stock now?

What is the primary business of Olema Pharmaceuticals?

Olema Pharmaceuticals, or OLMA, is a biopharmaceutical company focused on developing innovative treatments for cancer. They work on targeted therapies to improve patient outcomes and aim to address unmet medical needs in oncology. Their research emphasizes precision medicine to provide effective solutions for various cancer types.

What is the ticker symbol for Olema Pharmaceuticals?

The ticker symbol for Olema Pharmaceuticals is NASDAQ:OLMA

Does Olema Pharmaceuticals pay dividends?

No, Olema Pharmaceuticals does not pay dividends

What sector is Olema Pharmaceuticals in?

Olema Pharmaceuticals is in the Healthcare sector

What industry is Olema Pharmaceuticals in?

Olema Pharmaceuticals is in the Biotechnology industry

What country is Olema Pharmaceuticals based in?

Olema Pharmaceuticals is headquartered in United States

When did Olema Pharmaceuticals go public?

Olema Pharmaceuticals's initial public offering (IPO) was on 19 November 2020

Is Olema Pharmaceuticals in the S&P 500?

No, Olema Pharmaceuticals is not included in the S&P 500 index

Is Olema Pharmaceuticals in the NASDAQ 100?

No, Olema Pharmaceuticals is not included in the NASDAQ 100 index

Is Olema Pharmaceuticals in the Dow Jones?

No, Olema Pharmaceuticals is not included in the Dow Jones index

When was Olema Pharmaceuticals's last earnings report?

Olema Pharmaceuticals's most recent earnings report was on 12 November 2024

When does Olema Pharmaceuticals report earnings?

The next expected earnings date for Olema Pharmaceuticals is 11 March 2025

Should I buy Olema Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions